Delivering therapeutic agents to the heart has long been a formidable challenge. While cardiovascular diseases remain the world’s leading cause of mortality, modern therapeutic strategies—including RNA medicines, protein drugs, and gene-editing tools—struggle to reach the myocardium in meaningful amounts. The heart’s unique structural and physiological barriers have historically limited the success of drug delivery systems (DDS), particularly for nucleic acids that require efficient intracellular transport.
A groundbreaking 2025 study published in PNAS, titled “Systemic delivery of biotherapeutic RNA to the myocardium transiently modulates cardiac contractility in vivo”, authored by Dr. Vladimir Muzykantov and colleagues, marks a pivotal advancement in this field. The authors demonstrate a cardiotropic lipid nanoparticle (cLNP) capable of delivering RNA therapeutics directly to cardiomyocytes through intravenous injection, achieving meaningful functional modulation of cardiac contractility. This represents a major shift in the landscape of extrahepatic nucleic acid delivery.
BOC Sciences is honored to welcome the author of this breakthrough study as our upcoming webinar speaker.
As BOC Sciences prepares to host Dr. Vladimir Muzykantov for our webinar on cognizant versus fortuitous nanocarrier targeting, this newly published research serves as a perfect scientific backdrop, offering fresh insights into how vascular targeting principles are applied in practical, high-impact cardiovascular innovations.
- Free Webinar: Delivery Nanocarriers to Desirable Vascular Destinations: Fortuitous Tropism vs. Cognizant Targeting
- Date & Time: December 12th, 2025 10:00 EST
- Speaker: Dr. Vladimir Muzykantov — a leading pioneer in nanomedicine and targeted drug delivery, and the Founders Professor of Nanoparticle Research at the University of Pennsylvania.
- Organizer: BOC Sciences
- Register: REGISTER HERE
- More Drug Delivery Services You May Also Be Interested In:
Nanotechnology in Drug Delivery
Carbohydrate-Based Drug Delivery
I. Why Cardiac Delivery Is One of Medicine’s Hardest Problems?
Despite tremendous progress in multiple therapeutic areas, delivering drugs to the heart remains one of the most complex and stubborn challenges in modern medicine. Unlike organs such as the liver or spleen—which naturally accumulate circulating nanoparticles—the heart possesses structural and physiological properties that strongly resist the entry and retention of therapeutic agents. These barriers collectively create an environment where even well-designed drug delivery systems struggle to achieve meaningful tissue penetration.
1. Endothelial Barrier Tightness
The myocardial vasculature is lined with exceptionally tight endothelial junctions, far more restrictive than those found in fenestrated hepatic sinusoids. As a result, nanoparticles and macromolecules circulating in the bloodstream face significant difficulty crossing into the cardiac interstitium. This tight barrier minimizes unintended fluid accumulation but also severely limits therapeutic access.
2. Extremely Rapid Clearance
The heart’s constant mechanical activity contributes to extremely efficient lymphatic drainage, rapidly clearing any material that manages to enter the interstitial space. Nanocarriers that might linger in other organs are therefore quickly removed from the myocardium, reducing their chance to interact with cardiomyocytes long enough to deliver functional payloads.
3. Dense Myocardial Architecture
Cardiomyocytes are arranged in densely packed, highly organized bundles, leaving very little extracellular room for nanoparticle diffusion. This anatomical compactness is essential for coordinated contraction but creates a physical barrier for drug penetration, further shrinking the already small window for therapeutic interaction.
4. Hepatic Uptake Outcompetes Cardiac Targeting
Compounding these intrinsic challenges is the overwhelming dominance of apolipoprotein E–mediated liver uptake, which rapidly redirects most intravenously administered lipid-based nanoparticles toward hepatocytes and macrophages. This natural biodistribution pattern masks any subtle or potential affinity a formulation might possess for the heart, making extrahepatic delivery—especially to the myocardium—extremely difficult to achieve.
Because of the combined effects of these barriers, many experimental delivery systems showing promise in vitro fail to demonstrate meaningful in vivo myocardial accumulation. Consequently, the field has long relied on invasive approaches such as direct intramyocardial injection, which are not scalable for routine clinical therapies. These enduring obstacles explain why effectively targeting the heart via systemic administration has remained one of the most persistent unmet challenges in drug delivery science.
II. A Serendipitous Discovery: Cardiotropism Unmasked by ApoE Depletion
The breakthrough reported in this study emerged from what can only be described as a fortuitous and scientifically intriguing observation. When the research team examined lipid nanoparticle behavior in animals lacking apolipoprotein E (apoE)—either through genetic knockout or through transient siRNA-induced depletion—they noted an unexpected phenomenon: a distinct and robust accumulation of certain LNP formulations in the heart. Under typical physiological circumstances, apoE rapidly directs circulating nanoparticles toward the liver, masking any subtle tissue-specific tropisms. However, once apoE was removed from the equation and hepatic sequestration was substantially reduced, this previously hidden cardiotropic signature became strikingly apparent.
This cardiotropic behavior was not deliberately engineered through ligand design or surface modification, but rather revealed through the altered biodistribution landscape created by apoE depletion. Once the dominant hepatic uptake pathway was suppressed, the intrinsic—and previously overshadowed—interaction between the cLNP formulation and the cardiac compartment emerged with remarkable clarity. Key experimental findings include:
- Rapid accumulation in the myocardium within 30 minutes post-injection, indicating an efficient and direct pathway of cardiac access.
- Dramatically elevated heart uptake in apoE-depleted animals compared to wild-type controls, highlighting the central regulatory role of apoE in determining systemic nanoparticle fate.
- Localization inside cardiomyocytes, not merely passive vascular retention, confirming that the nanoparticles successfully reached and penetrated myocardial tissue rather than remaining confined to the vasculature.
- Persistence across multiple species including mice and rats, suggesting that this observation is not a strain-specific anomaly but may reflect a more generalizable biological principle.
These observations collectively suggest that the heart possesses previously unappreciated molecular or biophysical mechanisms that facilitate nanoparticle entry, especially when the competitive pull of liver uptake is relieved. Such mechanisms may involve unique endothelial features, local protein interactions, or circulation-driven transport dynamics that only become apparent when the systemic biodistribution landscape shifts.
This discovery fits elegantly into the broader theme of fortuitous targeting, one of the two strategic frameworks that Dr. Vladimir Muzykantov will discuss in the webinar:
- Cognizant (rational, receptor-based) targeting
- Fortuitous (empirically discovered) targeting
The cardiotropic LNP described here is a compelling and illustrative example of the latter, demonstrating how unexpected biodistribution patterns can open new avenues for therapeutic innovation—especially in organs long considered difficult to reach.
III. Functional Delivery: Modulating Contractility by Targeting SERCA2A
To evaluate whether this cardiotropic LNP platform could deliver biologically significant and functionally active payloads, the researchers encapsulated siRNA targeting Atp2a2, the gene encoding SERCA2A. SERCA2A is a pivotal calcium-handling protein responsible for pumping Ca²⁺ back into the sarcoplasmic reticulum, thereby orchestrating both the contraction and relaxation phases of cardiomyocyte activity. Because of its central role in cardiac physiology—and its known dysregulation in several forms of heart failure—SERCA2A is an ideal marker for testing whether a delivery system can effectively modulate intracellular targets within the myocardium. The study’s major findings include:
1. Near-Complete Knockdown of SERCA2A
Within just three days of intravenous administration, the cLNP/siRNA formulation achieved marked and near-complete suppression of SERCA2A protein levels in myocardial tissue. This rapid and substantial knockdown provides strong evidence that the delivered siRNA not only entered cardiomyocytes but also remained intact and functional within the cytosolic environment. Such efficiency is particularly noteworthy given how notoriously resistant cardiomyocytes are to nucleic acid uptake, underscoring the exceptional intracellular access provided by the cLNP system.
2. Predictable Physiological Effects
The physiological impact of SERCA2A silencing was clearly observable in ex vivo contractility assays, where cardiomyocytes isolated from treated animals demonstrated hallmark features of impaired calcium cycling, including:
- Decreased fractional shortening, reflecting reduced contractile strength
- Slower contraction kinetics, indicating diminished efficiency in force generation
- Slower relaxation rates, consistent with impaired Ca²⁺ reuptake into the sarcoplasmic reticulum
These functional signatures are canonical consequences of SERCA2A inhibition, indicating that the delivered siRNA produced precisely the expected biological response. This alignment between genetic modulation and physiological outcome serves as compelling validation of both the targeting specificity and the functional potency of the cLNP platform.
3. Transient, Reversible Modulation
Importantly, SERCA2A expression levels were observed to recover naturally over the subsequent days, demonstrating that the intervention was temporary and reversible. This reversibility is a desirable characteristic for many cardiac applications, as it allows therapeutic effects to be finely tuned without permanently altering the myocardium. Such temporal control is particularly important in safety-sensitive organs like the heart, where long-lasting or irreversible gene modulation may introduce unpredictable risks.
4. No Overt Myocardial Damage
Comprehensive histological evaluation and inflammatory marker analysis revealed no evidence of structural injury, immune activation, or pathological remodeling in treated cardiac tissue. The absence of detectable toxicity highlights the favorable safety profile of the cLNP system under the tested conditions, suggesting that the platform can deliver potent gene-silencing effects without eliciting off-target damage or harmful inflammation.
Taken together, these findings demonstrate that the cLNP platform possesses the rare combination of cardiac targeting capability, intracellular delivery efficiency, predictable functional modulation, and reassuring safety performance. This positions the technology as a highly promising strategy for systemic gene regulation within the heart—an achievement that has eluded the field for decades and holds significant potential for future therapeutic development.
IV. mRNA Delivery and Gene Editing in Cardiomyocytes
The study extends beyond siRNA to test whether cLNP can also deliver functional mRNA—a crucial requirement for gene-editing, gene-replacement, and regenerative strategies. Using Cre recombinase mRNA in a fluorescent reporter mouse model, the authors observed clear evidence that the cLNP system is capable of mediating robust gene modulation directly within cardiomyocytes.
The data revealed:
- Robust Cre-mediated recombination in cardiomyocytes, demonstrating that the delivered mRNA is efficiently translated and can drive intracellular events requiring substantial protein expression.
- Significantly higher editing efficiency with cLNP compared to non-cardiotropic controls, underscoring the unique and previously unrecognized cardiac access that this formulation enables.
- A convincing demonstration that cLNP can support gene-editing workflows inside the heart, an ability that has historically been challenging due to poor intracellular delivery of nucleic acids to cardiomyocytes.
This milestone opens the door to a broad range of therapeutic interventions that rely on precise genetic modulation, including:
- Gene correction for inherited cardiomyopathies
- Modulation of electrophysiological genes to treat arrhythmias
- Regenerative and reprogramming strategies aimed at cardiac repair
- Precision editing approaches for molecular cardiology
With mRNA-based medicines and gene-editing technologies rapidly advancing across the biotechnology landscape, the emergence of a functional cardiac delivery vehicle has profound implications for future clinical translation. It suggests that therapies once limited by delivery barriers may now become realistic options for treating a variety of cardiac conditions.
V. Mechanistic Insights: ApoE as a Gatekeeper of Systemic Targeting
A major conceptual contribution of this study is its detailed examination of how ApoE shapes nanoparticle biodistribution and, in particular, how its presence or absence acts as a powerful determinant of organ-selective targeting. The accompanying physiologically based pharmacokinetic (PBPK) modeling provides several key insights:
- In wild-type animals, ApoE drives 80–85% of total clearance of LNP into the liver and spleen, effectively dominating systemic biodistribution and suppressing extrahepatic targeting.
- ApoE substantially reduces cardiac uptake affinity—by roughly an order of magnitude, making the heart an almost inaccessible organ for standard LNP formulations.
- Without ApoE, previously obscured saturable cardiac uptake pathways become dominant, revealing an innate potential for cardiac engagement that has long been masked by hepatic clearance.
This framework aligns closely with the emerging understanding of protein corona effects, in which spontaneously adsorbed plasma proteins guide nanoparticles toward specific tissues. In conventional scenarios, the corona encourages preferential liver uptake, reinforcing the dominance of hepatic sequestration. Here, however, suppressing ApoE exposes a new biodistribution pattern—one that suggests the existence of latent cardiac trafficking receptors or transport dynamics not previously exploited in drug delivery.
The authors emphasize that elucidating these mechanisms could transform this serendipitous discovery into a rational, predictable strategy for cognizant cardiac targeting, shifting the field from accidental findings to deliberate design.
VI. Implications for Cardiovascular Therapeutics
The cardiotropic LNP platform described in this study arrives at a pivotal time in drug development. As nucleic acid therapeutics transition from early experimental concepts to mainstream applications—from mRNA vaccines to in vivo gene editing—the need for organ-specific delivery technologies has become more pressing than ever. The heart, long considered an exceptionally difficult target, now appears newly accessible through this cLNP platform. Potential application areas include:
1. Heart Failure
Enabling targeted modulation of calcium-handling proteins, metabolic regulators, or fibrotic pathways—core mechanisms implicated in the progression of heart failure.
2. Arrhythmias
Delivering RNA tools that precisely adjust ion channel expression, conduction-modifying genes, or pacemaker cell characteristics, allowing for highly tailored electrophysiological interventions.
3. Myocardial Infarction & Ischemia-Reperfusion
Supporting acute or post-injury cardiac care through delivery of:
- Anti-inflammatory molecules
- Pro-survival or cytoprotective genes
- Angiogenic factors promoting vascular recovery
- Regeneration-associated RNA to facilitate tissue repair
4. Genetic Cardiomyopathies
Opening pathways for direct in vivo gene correction using CRISPR, base editors, or prime editing tools targeting genes such as:
- Titin (TTN)
- Lamin A/C (LMNA)
- Myosin family genes
- Desmosomal proteins
5. Cardiotoxicity Prevention
Providing protective RNA therapeutics to mitigate drug-induced damage, particularly in oncology patients receiving cardiotoxic chemotherapies like anthracyclines.
Because the cLNP platform supports both mRNA and siRNA delivery, it emerges as a versatile chassis capable of supporting a wide range of therapeutic strategies for cardiovascular disease, from gene silencing to protein expression and gene editing.
VII. Limitations, Opportunities, and the Road Ahead
While the findings of this study are highly promising, several important challenges and areas for future development remain. Addressing these will be essential to advance cardiotropic nanocarriers toward clinical translation.
- ApoE Depletion Requirement: At present, robust cardiac targeting relies on suppressing ApoE, a strategy not directly applicable to clinical practice. Future LNP designs must achieve similar or greater cardiac selectivity without competing against the liver’s dominant ApoE-driven uptake pathway.
- Identification of the Cardiac Uptake Mechanism: The precise biological or physicochemical mechanism enabling cLNP entry into cardiomyocytes remains unclear. Whether this process involves endothelial receptors, unique mechanical forces generated during cardiac contraction, lipid-specific interactions, or distinct protein corona signatures requires deeper investigation.
- Scalability and Human Translation: Rodent cardiac physiology differs substantially from that of humans. Factors such as coronary blood flow, vascular shear stress, and plasma protein composition may alter delivery outcomes, highlighting the need for large-animal studies and translational modeling.
- Improving Delivery Efficiency: Even with enhanced tropism, the absolute percentage of nanoparticles reaching cardiomyocytes must be increased to meet therapeutic thresholds, particularly for disorders requiring high editing efficiency or large gene payloads.
Despite these challenges, the current work stands as a critical proof of concept—demonstrating that systemic, noninvasive, and functionally meaningful cardiac delivery is not only possible, but achievable with lipid nanoparticle platforms. This breakthrough opens a promising new pathway in a field that has historically faced decades of frustration and technical obstacles.
BOC Sciences: Accelerating Innovation in Drug Delivery Systems
As pharmaceutical and biotech developers race to design smarter, safer, and more effective delivery platforms, BOC Sciences provides end-to-end support across virtually every branch of DDS development. Our capabilities include:
Nanoparticle & Nanotechnology-Based Systems
- Lipid nanoparticles (LNP)
- Polymer-based drug delivery
- Cell-membrane–coated nanocarriers
- Functionalized, ligand-targeted nanocarriers
- Ionizable lipid design
- Nanocarrier optimization and characterization
RNA Therapeutics Delivery
- mRNA, siRNA, and saRNA formulation
- Encapsulation and stability optimization
- Extracellular vesicle and exosome-based delivery
- Customized nanoparticle screening platforms
Cell-Based Delivery and Biomaterial Platforms
- Exosome drug delivery engineering
- Microspheres and hydrogels
- Peptide-based carriers & carbohydrate-based carriers
- Multi-layered and hybrid DDS
Specialized Cardiac & Vascular Targeting Expertise
- Endothelial-targeted formulations
- Vascular ligand screening
- Delivery optimization for ischemia, inflammation, and thrombosis models
Our integrated R&D ecosystem is designed to accelerate the transition from concept to clinic, helping partners explore both cognizant and fortuitous targeting strategies—central themes in Dr. Vladimir Muzykantov’s work.
Join Our Webinar to Explore the Future of Vascular Targeting
Delivery Nanocarriers to Desirable Vascular Destinations: Fortuitous Tropism vs. Cognizant Targeting
This webinar session will explore:
- The mechanistic principles underlying vascular targeting
- Differentiation between rational ligand-based targeting and serendipitous discovery
- Advances in nanomedicine for acute cardiovascular pathologies
- How examples like cardiotropic LNPs are reshaping the field
- Strategies to design safe, precise, and high-performance vascular DDS
The cardiotropic LNP study represents a turning point in cardiac drug delivery—a domain that has historically resisted innovation due to the heart’s complex structural, biomechanical, and vascular barriers. By demonstrating effective, systemic, and functional RNA delivery to cardiomyocytes, Dr. Vladimir Muzykantov and colleagues have revealed new possibilities in nanomedicine and RNA therapeutics. As cardiovascular disease continues to impose staggering global health burdens, breakthroughs like this one carry profound implications. They open the door not only to future therapeutics but also to a deeper understanding of the biological principles governing nanoparticle transport, endothelial interaction, and organ-selective delivery.
BOC Sciences is honored to spotlight this pioneering work and to welcome Dr. Vladimir Muzykantov to our webinar, where he will further illuminate the scientific journey from discovery to translational potential.